Karo Pharma publishes prospectus relating to the rights issue and receives approval to change listing venue to Nasdaq First North Growth Market
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.The prospectus relating to the rights issue in Karo Pharma Aktiebolag (“Karo Pharma”) of approximately SEK 2.5 billion (the “Rights Issue”) has